Surmodics Q3 2024 Adj. EPS $(0.27) Beats $(0.33) Estimate, Sales $30.341M Beat $30.006M Estimate
Portfolio Pulse from Benzinga Newsdesk
Surmodics reported its Q3 2024 earnings with an adjusted EPS of $(0.27), beating the estimate of $(0.33). The company also reported sales of $30.341 million, surpassing the expected $30.006 million.
July 31, 2024 | 11:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Surmodics reported better-than-expected Q3 2024 earnings with an adjusted EPS of $(0.27) compared to the $(0.33) estimate and sales of $30.341 million versus the $30.006 million estimate.
Surmodics' better-than-expected earnings and sales figures are likely to positively impact its stock price in the short term. Beating both EPS and sales estimates typically boosts investor confidence and can lead to a stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100